Crossmark

Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity

Crossref DOI link: https://doi.org/10.1016/j.rceng.2022.12.001

Published Print: 2023-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Carretero-Gómez, Juana

Carrasco-Sánchez, Francisco Javier

Fernández-Rodríguez, José María

Casado-Escribano, Pedro

Miramontes-González, José Pablo

Seguí-Ripoll, José Miguel

Ena, Javier

Arévalo-Lorido, José Carlos
License Information

Text and Data Mining valid from 2023-03-01

stm-asf valid from 2023-03-01

stm-asf valid from 2023-03-01

stm-asf valid from 2023-03-01

stm-asf valid from 2023-03-01

stm-asf valid from 2023-03-01
More Information

This article is maintained by: Elsevier

Article Title: Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity

Journal Title: Revista Clínica Española (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.rceng.2022.12.001

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.rce.2022.11.007

Content Type: article

Copyright: © 2022 Published by Elsevier España, S.L.U.